Biolife Solutions Inc. (BLFS)
BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.02 per share a year ago.
BioLife: Back To Basics Is Getting Traction (Rating Upgrade)
After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions (BLFS): Here's What You Should Know
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Roderick de Greef - CEO & Chairman Troy Wichterman - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Chad M. Wiatrowski - TD Cowen, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Yi Chen - H.C.
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.06 per share a year ago.
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by.
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago.
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers.
